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Abstract: Ionizing irradiation induces acute and chronic injury to tissues and organs. 
Applications of antioxidant therapies for the management of ionizing irradiation injury fall 
into three categories: (1) radiation counter measures against total or partial body irradiation; 
(2) normal tissue protection against acute organ specific ionizing irradiation injury; and (3) 
prevention of chronic/late radiation tissue and organ injury. The development of antioxidant 
therapies to ameliorate ionizing irradiation injury began with initial studies on gene therapy 
using Manganese Superoxide Dismutase (MnSOD) transgene approaches and evolved into 
applications of small molecule radiation protectors and mitigators. The understanding of the 
multiple steps in ionizing radiation-induced cellular, tissue, and organ injury, as well as total 
body effects is required to optimize the use of antioxidant therapies, and to sequence such 
approaches with targeted therapies for the multiple steps in the irradiation damage response. 
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Ionizing irradiation induces sequential steps of cellular, tissue, organ, and total body injury [1–15]. 
Within fractions of a second during ionizing irradiation exposure, water in cells is hydrolyzed and free 
radicals are generated, including superoxide and hydroxyl radical, which are detectable in  
experiments [16–28]. Sequential steps involve the generation of hydrogen peroxide [29]. At this stage 
(seconds), and for minutes, hours, and days after exposure, the management of oxidative stress from 
ionizing irradiation shares many steps common with other forms of injury, including: Hyperbaric oxygen 
injury, hypoxia, chemical toxin exposure, heat, ultraviolet irradiation, chemical toxicity, and  
infection [30–33]. Over days after irradiation, tissues and organs respond to a sequence of events 
culminating in an acute inflammatory response [1,30,31,34–44]. Somewhat unique to radiation injury is 
the subsequent latent period during which many injury markers, including histopathologic effects are 
undetectable [32,45–55]. Tissue volume, tissue type, and genetic factors control the onset of a final 
late/chronic radiation injury phase, which includes fibrosis and scarring [48]. 
In recent years, attempts to ameliorate ionizing irradiation injury have utilized reagents and 
therapeutics common to the treatment of other forms of tissue and organ injury [56]. Prominent among 
these attempts has been the approach to utilize antioxidant therapies. Initial experiments using free 
radical scavengers include N-Acetyl-Cysteine (NAC) or the supplement/replenishing of antioxidant 
stores by delivering glutathione. These methods demonstrated some success in tissue culture and animal 
models [57–62]. However, true breakthroughs occurred with the molecular cloning and expression of 
transgenes for antioxidant enzymes, prominently the superoxide dismutases [63–67]. Replenishment of 
superoxide enzymes by protein delivery was ineffective compared to delivery of transgene for protein 
production [63,64]. The relatively cumbersome nature of producing transgenes for gene therapy 
invigorated the development of small molecule antioxidants with properties similar to the transgene 
products. Prominent in this category was the development of Tempo (Figure 1), a nitroxide with the 
capacity to scavenge free radicals and, through cycling of the nitroxide to hydroxyl-amine, to neutralize 
multiple free radicals for each molecule of Tempo [59,68]. Finally, the role of mitochondria in the 
mechanism of irradiation apoptosis prompted the development of mitochondrial-targeted Tempo  
(GS-nitroxides and triphenylphosponium nitroxides) [29,68–74]. Initial success in animal models using 
mitochondrial-targeted antioxidants has uncovered multiple steps in the response to ionizing irradiation, 
which cannot be explained solely by individual cellular responses (nuclear-mitochondrial signaling and 
apoptosis). These realizations have led to new therapeutic approaches including the application of new 
drugs, with actions distinct from the antioxidant approach. Nevertheless, three categories of applications 
of mitochondrial-targeted antioxidants have gained prominence as potential therapeutic strategies toward 
the amelioration of irradiation injury. 








Figure 1. Structures of 4-Amino-Tempo (A); XJB-5-131 (B); JP4-039 (C); and MMS350 (D). 
2. Experimental Section 
2.1. Mice 
The C57BL/6NHsd, FVB/N, 129/Sv, and Fanconi Anemia (FA) Fancd2−/− mice on both the 129/Sv 
and C567BL/6 genetic backgrounds have been described previously [75,76]. Mice were housed  
four per cage according to the Institutional IACUC Protocol, and fed standard laboratory chow and 
deionized water. 
2.2. Tissue Culture Experiments 
Techniques for long-term bone marrow culture, establishment of bone marrow stromal cell lines, and 
Interleukin 3 (IL-3) dependent hematopoietic progenitor cell lines have been published [36,77]. Methods 
for growing fresh bone marrow colony forming units CFU-GEMM have been published previously [78]. 
2.3. Manganese Superoxide Dismutase-Plasmid Liposomes 
The techniques for production and administration of MnSOD-PL have been described  
previously [1,26]. Briefly, the MnSOD transgene was expressed in plasmid vector, the plasmid was 
grown according to published methods, and it was delivered in a liposome preparation of cationic 
liposomes by an intra-tracheal installation [1–3], intravenous route [79–81], intra-oral [40], or 
intraesophageal [6,82] route according to previous publications. 
2.4. GS-Nitroxides and JP4-039 
The mitochondrial-targeted nitroxide based on 4-Amino-Tempo (Figure 1) have been described in 
detail [42,68,83,84]. GS-nitroxide drugs were prepared by attachment of modified gramicidin S 
fragments to the nitroxide, thus generating mitochondrial targeted agents of various lengths (Figure 1A–C). 
These included the larger molecule XJB-5-131 [85], and a shorter analog, JP4-039, which have been 
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shown to be radiation mitigators (Figures 2 and 3) [68]. JP4-039 has been demonstrated to be effective 
as a total body radiation protector and mitigator [80,86] in both C57BL/6NHsd mice (Figure 3) and in 
C3H/HeN mice (Figure 4). The laboratory of Dr. Peter Wipf of the Department of Chemistry at the 
University of Pittsburgh synthesized XJB-5-131, JP4-039 as well as MMS350, a highly water soluble 
sulfoxide with a different mechanism of action for prevention of radiation damage. 
2.5. Assays for Antioxidant Stores 
The Trolox assay for antioxidant stores has been published in detail and these methods have been 
previously described [75,76]. 
2.6. Assays for Apoptosis, Mitochondrial Content, and Mitochondrial Number 
The methods for quantitation of ionizing irradiation effects on mitochondria have been published 
previously [28,87]. 
 
Figure 2. Effective radiation mitigation by two GS-nitroxide analogs (XJB-5-131 and  
JP4-039). Groups of 15 C57BL/6NHsd mice received total body irradiation, and then 24 h 
later intravenous administration of 100 μL of F14 liposomes containing either XJB-5-131 or 
JP4-039, standardized for equimolar concentration. The heavier molecular weight of  
XJB-5-131 requires larger quantities to achieve an equimolar concentration with JP4-039. 
There was equivalent radiation mitigation by both drugs. 
 





























Figure 3. Effective mitigation of total body irradiation damage in C57BL/6NHsd mice by 
intravenous administration of JP4-039. Experiments shown are over a course of a year 
accounting for the TBI dose “drift” of the LD50/30. At 3 different time points during a single 
calendar year, experiments were carried out delivering JP4-039/F15 in 100 μL volume 
containing 20 mg/kg drug, to mice. In these experiments, the LD50/30 was noted to “drift” 
over the course of the year and could not be explained by changes in the Cesium-70 Gamma 
Cell irradiator, supplier of mice, age of mice, gender of mice (all were female), diet, or other 
factors in the animal care facility. In all experiments, despite the “drift” of the LD50/30,  
JP4-039 was an effective mitigator against total body irradiation. 
 
Figure 4. Mitigation of total body irradiation damage to C3H/HeNHsd mice by intravenous 
JP4-039/F14 antioxidant small molecule therapy. Groups of C3H/HeNHsd mice (n = 15) 
received total body irradiation, and 24 h later intravenous administration of 100 μL of F14 
liposomes containing 100 μg of JP4-039. Survival was quantitated, and there was a 
significant increase in survival in mice given JP4-039. 
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3. Results and Discussion 
3.1. Antioxidant Therapies to Prevent and/or Mitigate Total Body Irradiation Injury 
Two applications of antioxidant therapies in ionizing irradiation damage have recently  
been described. Protection against total body irradiation damage has been demonstrated with  
MnSOD-plasmid liposomes administered intravenously 24 h prior to total body irradiation [79,81].  
In two model systems, one in which MnSOD-PL was given alone [79], and in another system 
supplemented with an antioxidant diet delivered after irradiation [81], improved survival of both male 
and female mice was demonstrated. The 24 h time point before irradiation was chosen based on previous 
studies that demonstrated a requirement for this time to get transgene into cells [66,88–93], facilitate 
nuclear migration, insertion of the plasmid into the nucleus, production of RNA for MnSOD, production 
of MnSOD, and then transport of the mitochondrial targeted SOD to the mitochondria, where radiation 
protection and mitigation actions were demonstrated [77,94–96]. Tissue culture studies demonstrated the 
requirement for mitochondrial targeting. In initial studies, cytoplasmic SOD1 (Cu/ZnSOD) was 
demonstrated to have little radioprotective or mitigation effect. However, when the mitochondrial 
targeting sequence from SOD2 (MnSOD) was added to Cu/ZnSOD, the molecule targeted the 
mitochondria and was radiation protective [36,49]. In contrast, when the mitochondrial targeting 
sequence was removed from the MnSOD transgene product, little radiation protection was seen, and 
gene product was concentrated in the cellular cytoplasm [49]. 
Antioxidant therapies to prevent total body irradiation damage were extended by the development of 
small molecule SOD mimics [17–19,42,70,97–101]. One strategy utilized in our laboratory was to 
increase the effectiveness of the nitroxide 4-Amino-Tempo (4-AT) by facilitating a mitochondrial 
enrichment [68]. Several GS-nitroxide variants were developed in the laboratory of Peter Wipf,  
Ph.D. [42,102,103]. Mitochondrial targeting was achieved by using a hemigramicidin analog attached 
to 4-Amino-Tempo [68]. Two different GS-nitroxides were compared for in vivo radiation mitigation, 
when delivered 24 h after total body irradiation. Figure 2 demonstrates the similar effectiveness of  
XJB-5-131, which shows a 300–600-fold mitochondrial concentration capacity, specifically in the inner 
mitochondrial membrane, compared to JP4-039, a molecule with a truncated mitochondrial targeting 
sequence, and a ca. 20-30-fold increased mitochondrial concentration. As shown in Figure 2, both 
molecules delivered in equimolar concentration 24 h prior to total body irradiation showed significant 
mitigation capacity. 
The difference between radiation protection and mitigation has particular relevance for the Radiation 
Counter Measures Program of the National Institutes of Allergy and Infectious Disease (NIAID) of the 
National Institutes of Health (NIH) [89]. Delivery of a potent preventive drug prior to irradiation, which 
can target mitochondria and prevent the depletion of antioxidant stores has great relevance for first 
responders in an irradiation incident, where accumulation of radio-isotopes might be expected, or 
whether further exposure to photon or high linear energy transfer particle (neutron, proton) irradiation 
might occur. However, the radiation protection strategy is not relevant to victims of a radiation terrorist 
event or nuclear reactor damage in which irradiation exposure would take place prior to the 
administration of drugs. Delivery of an irradiation modifying drug 24 h or later after irradiation is 
considered “mitigation”, and thus the radiation mitigator properties have been a focus of the Radiation 
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Counter Measure Program. Figure 2 demonstrates that both XJB-5-131 and JP4-039 were effective 
mitigators despite a significant difference in mitochondrial concentration capacity. This data argues that 
the difference between a 30-fold and 600-fold mitochondrial concentration capacity might not be 
relevant to a successful total body radiation mitigation. However, other studies have demonstrated the 
effectiveness of XJB-5-131 in crossing the blood brain barrier to ameliorate the toxicity of traumatic 
brain injury, while JP4-039 does not cross the blood brain barrier [85]. 
The mechanism of total body irradiation protection and mitigation by both gene therapy (MnSOD-PL), 
and small molecule antioxidants (GS-nitroxides) [16,42,57,58,77,79,83,94–97,104–108] may not be 
attributable solely to direct cellular effects. The bystander effect of both radiation injury and amelioration 
of irradiation damage by radiation mitigator drugs has been well documented in the radiobiology 
literature [76]. Most recently, using Fancd2−/− (129/Sv) mice, a bystander effect of partial body 
irradiation was demonstrated. Head and neck irradiation of mice demonstrated significant suppression 
of bone marrow at the distant femur site [76]. Application of a mitochondrial targeted antioxidant 
radiation protector/mitigator to the oral cavity/oropharynx, to be described in the next section, not only 
protected the treated tissue, but also suppressed the bystander effect of radiation damage. A positive 
bystander effect also applies to the application of radiation protectors and mitigators. Uptake and 
mitochondrial targeting of drug in a relatively small percentage of cells within an organ can confer organ 
radiation protection or mitigation [1,40,90]. This was demonstrated with esophageal delivery of 
hemagglutin-epitope tagged MnSOD transgene product, which, when delivered prior to irradiation 
conferred significant organ radioprotection, while the transgene product was only detectable in a small 
fraction of cells within that organ [39]. These data were confirmed in both lungs and esophagus as well 
as oral cavity organ specific radiation protection strategies (These data will be described in the  
next section regarding acute radiation injury to specific organs and targeted therapies using the  
antioxidant approach). 
3.2. Antioxidant Radioprotection and Radiation Mitigation in Organ Specific/Localized Applications 
The effectiveness of the antioxidant approach in both preventing and ameliorating irradiation injury 
was demonstrated in model systems utilizing both MnSOD-PL gene therapy [45], and also more recently 
with targeted GS-nitroxides [68]. 
Organ specific radioprotection using MnSOD-PL has been demonstrated in bladder [37], intestine [46], 
oral cavity/oropharynx [40,41], esophagus [6,109], lung [1,90], and in fetal mice in vivo [80]. In each of 
these systems, MnSOD-PL administration utilized a localized liposomal free system, Herpes Virus 
vector or adenovirus vector administered transgene. Organ specific radiation protection/mitigation was 
demonstrated in each model system in mice or rats utilizing radiobiological parameters of injury 
including histopathology, organ function, physiologic monitors (bladder measurement of water and urea 
transepithelial transfer), and by assays for specific cellular damage including the apotag assay for 
apoptosis, and electron microscopic evidence of cell death [17–19,59,98,99,110]. 
Application of GS-nitroxides as organ specific radioprotectors followed the work of MnSOD-PL 
mediated radiation protection, and utilized the same organ specific radiation damage systems. JP4-039, 
which demonstrated significant total body irradiation protection and mitigation properties (described in 
the last section) was highly effective when delivered in formulations designed to keep drug localized to 
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a specific organ system [76]. JP4-039 was delivered in a liposomal emulsion containing Tween (F15), 
which was designed to keep the drug localized and in direct contact with cells exposed to the drug. The 
JP4-039/F15 formulation was a highly effective radiation protector and mitigator for esophagus and oral 
cavity/oropharynx [76,111]. In recent studies, JP4-039/F15 administration to both FA Fancd2−/− (129/Sv) 
and Fancd2−/− (C57BL/6) mice, as well as heterozygote and wild type litter mates showed significant 
protection and mitigation of damage to the oral cavity/oropharynx in both single fraction and fractionated 
irradiation [76,112]. In models of organ specific radiation protection/mitigation, principally designed for 
translational approaches in clinical radiotherapy, there has been great concern that antioxidant drugs 
would also protect tumors. Initial studies with MnSOD-PL as well as JP4-039/F15 demonstrated no 
protection of orthotopic lung tumors [9,41] or orthotopic head and neck cancer [96,112]. 
3.3. Antioxidant Therapy to Prevent Ionizing Radiation Late Effects 
There are several components to ionizing irradiation-induced late effects [59]. It has been 
demonstrated that volume of tissue/organ irradiated, total dose of irradiation, and in the case of clinical 
radiotherapy, the fraction size of radiation, all contribute to the severity and time of onset of late  
effects [48]. In clinical radiotherapy, late effects are most critical in producing organ failure [79]. Kidney, 
liver, lung, and esophageal irradiation are known to induce fibrosis, which can limit the effectiveness of 
treatment due to late side effects [48,50]. In the case of total body irradiation, late effects are most 
prominent after relatively low doses of irradiation that, while suppressing natural blood counts, do not 
lead to acute radiation damage. The most prominent late effect is the induction of cancer [79]. The 
molecular mechanism of irradiation late effects has been the subject of intense investigation. Antioxidant 
approaches to prevent late effects of irradiation have gained significant interest in recent years. Oxidative 
stress has been shown to be a chronic component of irradiation damage to tissues and organs. These 
oxidative stress events are detected in the lung years after therapeutic lung irradiation [57]. In animal 
models, markers of antioxidant stress are detected in irradiated lungs months after irradiation[54].  
A critical approach has been taken to utilize antioxidant therapies to ameliorate late effects. The 
administration of MnSOD-plasmid liposomes intravenously prior to irradiation has been shown to 
significantly improve acute survival measured by the lethal dose for 50% of mice at 30 days (LD50/30),  
but also to significantly ameliorate radiation late effects, prominently life shortening and  
carcinogenesis [79,113]. In a second series of experiments, mice given MnSOD-PL 24 h prior to 
irradiation were then placed on a novel antioxidant diet consisting of a wide variety of antioxidants and 
chemopreventive agents [81]. Under these conditions, surviving animals demonstrated significant further 
amelioration of radiation-induced life shortening. In both of these experiments, MnSOD-PL alone, or 
supplemented with an antioxidant diet, there was no increase in detectable cancers in mice surviving for 
prolonged periods after irradiation. 
There is much evidence to support a difference in the molecular mechanism of acute irradiation 
damage compared to late effects [54,55,114]. The administration of radioprotective MnSOD-PL into the 
lungs prior to irradiation was significant in preventing acute radiation pneumonitis and death. However, 
in a mouse model that received MnSOD-PL 100 days after irradiation, when late effects (radiation 
fibrosis) began to appear, late effects were not ameliorated [47]. Studies with pulmonary irradiation in a 
fibrosis prone mouse strain (C57BL/6NHsd) compared to a fibrosis resistant mouse strain 
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(C3H/HeNHsd) demonstrated a significant difference in radiation responses in the lungs with respect to 
the RT-PCR detected induction of RNA transcripts [55]. Fibrosis prone C57BL/6NHsd mice showed 
upregulation of TLR4 (Toll-Like Receptor 4) in the lung at the time of the initiation of fibrosis, while 
C3H/HeNHsd mice did not show upregulation of TLR4 [115]. 
Furthermore, the critical role of TGF-β in late irradiation fibrosis has been demonstrated in  
SMAD3−/− knockout mice [116,117], which demonstrated no irradiation-induced skin fibrosis, and no 
detectable radiation pulmonary fibrosis. Migration into the lungs of bone marrow stromal cell progenitors 
of lung fibroblasts has been shown to be a significant component of pulmonary fibrosis following 
irradiation. In an experiment in which wild type mice were chimeric for either SMAD3−/− fluorochrome 
labeled bone marrow stromal cells or wild type sex mismatched fluorochrome labeled bone marrow 
stromal cells, there were significant decreases in migratory capacity of the SMAD3−/− stromal cells into 
the lung contributing to radiation fibrosis [117]. Decreased motility of bone marrow stromal cells from 
SMAD3−/− mice was also characteristic of this genotype, suggesting further contribution to the fibrotic 
phenotype after irradiation of the motility of the stromal cells [116]. 
A recent advance in prevention of irradiation late effects has been the demonstration of a  
water-soluble dimethylsulfoxide analog, MMS350 (Figure 1), which, when administered to mice 
beginning 100 days after thoracic irradiation, significantly ameliorated fibrosis [54]. MMS350 has been 
shown to be easily administered in mL drinking water and is safely delivered to mice continuously after 
thoracic irradiation. 
Effects of irradiation have been shown to be common to other forms of toxic substance induced 
fibrosis. In recent studies of liver fibrosis, the involvement of specific cytokine receptors has been shown 
to be mediated at the level of the endothelial cells [118,119]. Involvement of endothelial cells in radiation 
fibrosis is also supported by studies with the von Willebrand Factor (vWF−/− knockout mice), which 
showed reduced fibrosis [120]. TLR4−/− (knockout) mice also showed reduced radiation fibrosis [115]. 
While the molecular biologic response is complex, endothelial cells appear to be gate-keepers for the 
signaling determining whether tissues repair radiation damage by restoration of tissue function or 
demonstrate a damage signal that solicits migration from the bone marrow into that organ of bone 
marrow stromal cell progenitors of fibrosis and induces the late fibrotic phenotype [110]. 
4. Conclusions 
There is much evidence to support an oxidative stress model for both acute ionizing irradiation effects 
and chronic oxidative stress mediated irradiation late effects. The initiation of therapeutic programs to 
combat radiation damage began with studies of transgene therapy utilizing mitochondrial targeted 
MnSOD-Plasmid Liposomes. These have been demonstrated in a recent clinical trial to be safe and 
effective in ameliorating acute irradiation toxicity to the esophagus [121]. MnSOD-PL therapy was 
shown to be effective in preventing radiation damage in total body experiments, and also in organ 
specific irradiation. The translation of this technology into clinical radiotherapy is in progress. A more 
recent development has been the use of MnSOD-mimic compounds and unnatural anti-antioxidants.  
XJB-5-131 and JP4-039 are enriched in mitochondria, and, consequently, seem to be particularly 
effective [122,123]. Triphenylphosphonium targeted nitroxides are also effective radiation protectors 
and mitigators [124]. Most recently, a highly water-soluble dimethylsulfoxide analog, MMS350, has 
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been shown to be safe when administered in drinking water and prevents both the acute and chronic 
effects of total body irradiation or pulmonary irradiation [54]. Further studies will be required to optimize 
the delivery of specific agents designed to prevent irradiation-induced apoptosis. Perhaps even more 
important is the mounting evidence that other forms of irradiation damage are involved in cellular, tissue, 
and organ responses to radiation, including necroptosis, ferroptosis, and alteration in oxidative 
lipidomics of tissues [43,71,101]. This damage leads not only to localized tissue injury, but also effects 
migration into tissues of inflammatory cells, which, through the production of inflammatory mediators, 
exacerbate the radiation response. Oxidative stress remains a prominent factor in ionizing irradiation 
damage and the use of antioxidants in both the fundamental study of radiation countermeasures and in 
clinical radiotherapy appears to be warranted. 
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